Stockreport

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting [Yahoo! Finance]

NeuroSense Therapeutics Ltd.  (NRSN) 
PDF CAMBRIDGE, Mass. April 18, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegene [Read more]